The cost of illness for adult asthma, analysed by disease severity, reveals a disproportionate use of medical resources by patients with severe disease. In Canada, severe asthma comprised 10% of the asthma population and accounted for 51% of all direct medical care costs and 54% of total asthma costs.2 Patients with severe disease were three times more likely to consult an asthma specialist, 15 times more likely to use an accident and emergency department and 19 times more likely to require hospitalization. In Australia, severe asthma comprises 6% of the adult asthma population and consumes 47% of the total annual costs for this disease; an estimate similar to that for the UK. Thus, on the grounds of unsatisfactory treatment, quality of life and health economics, there is a strong case for focusing attention on this group of asthma patients.
CYTOKINE AND MEDIATOR NETWORKS AS THE BASIS OF ASTHMA
Asthma is a multifactorial disease that spans the full spectrum of activity from mild seasonal symptoms to being severe and intractable. When classifying asthma by severity, the majority falls into the mild-moderate range and can be managed well with currently available drugs. It is also at this end of the disease spectrum and in those with atopy that most of our understanding of inflammatory and mediator mechanisms of asthma has been based. Application of immunohistochemistry, in situ hybridization (ISH) and reverse transcriptase polymerase chain reaction 
MECHANISMS OF ASTHMA SEVERITY AND CHRONICITY
There is overwhelming evidence to indicate that airway inflammation underlies the pathophysiology of asthma, but its relationship to disease severity is less clear. While there are eosinophils in the sputum, a persistent blood eosinophilia with increased circulating levels of eosinophil granule proteins broadly relates to disease severity. These measures are too variable to provide clinically useful markers to predict the level of airway inflammation.
The selective recruitment of cells from the microvasculature underlies the ongoing inflammation in severe and chronic disease. Increased mast cell, eosinophil and T cell survival through cytokine-mediated inihibition of apoptosis is also important.
Lung transplantation has shown that alone, with its lymphoid tissue, the lung is able to sustain ongoing asthma also emphasizing the importance of local factors.3 From a therapeutic standpoint the wide variation observed in these biomarkers in relation to the varied clinical phenotypes suggest complex cellular and mediator mechanisms.
Corticosteroids are highly effective anti-asthma drugs acting to reduce the inflammatory response. However, there are many patients in whom only partial relief is achieved even with high doses. In a well-defined population of'corticosteroid-resistant'
abnormalities of circulating monocyte and T-cell cytokine function have been described.4 However, such patients represent only a minority of the'difficult to control' asthmatics. The majority of asthma occurs in association with atopy, the predisposition to generate IgE in response to common environmental allergens through a Th-2-cell-dependent mechanism. Ongoing allergen-specific IgE production in severe disease provides the rationale for allergen avoidance and high altitude treatment. However, environmental interventions have no effect on non-allergic asthma and many patients with severe atopic disease only partially respond or fail to respond. Irrespective of atopy, powerful epidemiological studies have linked the total serum IgE to the presence of asthma and its level of disease progression.5 There have been very few long-term studies but what evidence does exist suggests that severe and poorly controlled asthma progresses because of an increasing, irreversible component.6 Severe and prolonged inflammation is almost always accompanied by tissue remodelling. The airways are no exception; however, the mechanism(s) involved and their contribution to the overall pathophysiology of severe and chronic asthma have not been evaluated. 
Continuous T-cell activation
Severe disease increasingly engages airway T cells leading to their oligoclonal expansion, activation with a mixed pattern of
Mast cell proteases
Tryptase, chymase, carboxypeptidase A and a cathepsin-G-like enzyme are also tightly bound to heparin which serves to preserve integrity and direct the specificity of the enzymes. Tryptase is the major secretory component of mast cells and comprises in excess of 20% of the total granule content of protein, and elevated concentrations have been detected in BAL fluid collected from patients with chronic severe asthma as well as from milder cases of atopic asthma. Evidence is emerging that this serine protease may act as a key mediator of disease. Tryptase is capable of participating in tissue remodelling, being able to cleave several components of the extracellular matrix (e. g., collagen VI, fibronectin) in addition to activating matrix metalloproteases (stromelysin). The generation of kinins by tryptase may have important consequences, and this enzyme can also degrade certain neuropeptides postulated to have a regulatory role in asthma (VIP, CGRP). Interacting directly with the cell surface, we have shown that tryptase can also enhance proliferation of epithelial cells, fibroblasts and smooth muscle cells, upregulate expression of ICAM-1, stimulate IL-8 release and induce eosinophil chemotaxis and activation, all of which are dependent upon preservation of the enzyme's catalytic site (Fig. 2) . [21] [22] [23] Chymase, a protease co-released with tryptase by MCTC, can also cleave several structural proteins and activate other tissuedegrading proteases (stromelysin, gelatinase A) as well as degrade selective cytokines. In addition, chymase is one of the most potent secretagogues of mucus-secreting cells to have been described when injected into laboratory animals. 24 We have shown that both tryptase and chymase, induce microvascular leakage and granulocyte accumulation (Fig. 3) .
Despite their potential importance as mediators, relatively little is known of the expression of proteases in mast cells of the respiratory tract of asthmatic patients. Numbers of mast cells in bronchial tissue (as revealed by immunostaining for tryptase) are not greatly altered in asthma, although the elevated concentration of tryptase in BAL fluid indicates that the mast cells are in a more activated state. The process of protease synthesis and the kinetics of release from mast cells are not well understood. Multiple cDNA have been cloned for tryptase, but the significance of this variation is not known. Sequences have also been derived for cDNA for chymase, and for other proteases which have been detected in mast cells including carboxypeptidase and cathepsin G. These advances now permit new approaches to be applied to answer basic questions on the biology of mast-cell proteases and to better understand their roles in bronchial asthma. 
